Cridanimod can increase progesterone receptor (PR) expression, with potential antineoplastic adjuvant activity. Cridanimod is able to induce the expression of PR in endometrial cancer. In combination with a progestin, cancer cells could be eradicated through increased PR-mediated signaling, leading to an inhibition of luteinizing hormone release from the pituitary gland, via a negative feedback mechanism, and, eventually, an inhibition of estrogen released from the ovaries.

58880-43-6

C15H11NNaO3

276.24

Sodium Cridanimod;Cridanimod Na;Cycloferon;XBIO-101;XBIO101;XBIO 101;Cridanimod sodium

DMSO:Soluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years